Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)35.86
  • Today's Change0.38 / 1.07%
  • Shares traded63.83k
  • 1 Year change+4.61%
  • Beta0.3138
Data delayed at least 15 minutes, as of May 03 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

  • Revenue in USD (TTM)10.43bn
  • Net income in USD1.31bn
  • Incorporated2005
  • Employees17.44k
  • Location
    Daiichi Sankyo Co LtdDaiichi Sankyo Bldg. A/B Kan3-5-1, Nihombashi Hon-choCHUO-KU 103-8426JapanJPN
  • Phone+81 362251111
  • Websitehttps://www.daiichisankyo.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Iqvia Holdings Inc14.98bn1.36bn40.54bn87.00k30.606.6316.332.717.307.3080.4233.670.5761--4.76172,229.905.223.246.804.0734.9634.329.066.03--3.240.69110.003.987.5524.4743.397.17--
Moderna Inc5.15bn-5.97bn47.86bn5.60k--3.74--9.29-15.66-15.6613.5133.460.25237.788.24920,178.60-29.2220.95-34.1329.5122.43---115.8232.103.91--0.04290.00-64.45119.28-156.37--46.22--
Daiichi Sankyo Co Ltd - ADR10.47bn1.31bn69.35bn17.44k52.436.2340.706.620.6840.6845.465.760.53661.123.99--6.73--8.53--74.07--12.55--2.40--0.0568--25.28--84.24------
Zoetis Inc8.73bn2.39bn76.34bn14.10k32.2015.0926.468.745.195.1918.9511.070.62161.007.05619,432.6017.0014.4719.6617.1870.1369.8027.3425.771.9416.820.565926.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.45bn484.00m80.72bn18.00k180.154.6212.082.940.35960.359621.8914.010.46462.696.221,525,000.000.77186.740.96328.1275.7878.641.6616.950.721211.88--81.22-0.60484.1523.370.7436-8.745.64
Bristol-Myers Squibb Co45.53bn-6.15bn89.17bn34.10k--5.4123.921.96-3.10-3.1022.158.140.47113.925.181,335,308.00-6.353.05-8.273.7675.9476.13-13.477.690.994715.570.7709133.63-2.5014.8126.8410.034.927.34
Vertex Pharmaceuticals Incorporated9.87bn3.62bn103.66bn5.40k28.875.8827.2710.5013.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Data as of May 03 2024. Currency figures normalised to Daiichi Sankyo Co Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Arctic Asset Management AS (Sweden)as of 29 Feb 2024142.07k0.01%
Ramirez Asset Management, Inc.as of 31 Dec 202365.92k0.00%
Madison Asset Management LLCas of 31 Dec 202365.68k0.00%
Nia Impact Advisors LLCas of 29 Feb 202436.21k0.00%
Yousif Capital Management LLCas of 31 Mar 202433.74k0.00%
RhumbLine Advisers LPas of 31 Dec 202320.97k0.00%
GAMMA Investing LLCas of 31 Mar 20242.42k0.00%
ShariaPortfolio, Inc.as of 04 Apr 20242.04k0.00%
Aperio Group LLCas of 31 Mar 20241.38k0.00%
Altair Advisers LLCas of 30 Nov 2023876.000.00%
More ▼
Data from 30 Nov 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.